In breast cancer, MMP2 and MMP9 were determined as important downstream effectors of PI3K/AKT signaling (Zhou et al., 2014) and MMP2 was shown to be activated by PI3K/AKT, regulated by RICTOR for the vasculogenic mimicry of tumor cells (Liang et al., 2017). Here, MMP9 is linked to breast carcinoma.